Vaccí contra la COVID-19: diferència entre les revisions
Contingut suprimit Contingut afegit
Línia 231:
!Fase actual<br />(participants)<br />Disseny
!Fase finalitzada{{efn-la|Última fase amb resultats publicats.}} (participants)<br />Resposta immunitària
!Pendent autorització
|- valign="top"
|'''[[Ad26.COV2.S]]'''<ref>{{ref-web|títol=A Study of Ad26.COV2.S in Adults|url=https://clinicaltrials.gov/ct2/show/NCT04436276|access-date= 23 agost 2020|website=[[ClinicalTrials.gov]]|data= 4 agost 2020|archive-date= 16 setembre 2020|archive-url=https://web.archive.org/web/20200916063346/https://clinicaltrials.gov/ct2/show/NCT04436276|url-status=live}}</ref><ref>{{ref-web|títol=A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants|url=https://clinicaltrials.gov/ct2/show/NCT04505722|url-status=live|archive-url=https://web.archive.org/web/20200926145744/https://clinicaltrials.gov/ct2/show/NCT04505722|archive-date= 26 setembre 2020|website=ClinicalTrials.gov|editor=US National Library of Medicine}}</ref>
Linha 243 ⟶ 242:
}}
| {{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=1045|description=Preimpressió. Seroconversió per a anticossos S superiors al 95%.}}
|{{Collapsible list|title=Emergència (3)|expand=yes
▲* Canadà<ref name="hcapps"/>
▲* EU: EMA<ref name="EU Ad26.COV2.S rolling review">{{cite press release | title=EMA starts rolling review of Janssen's COVID-19 vaccine Ad26.COV2.S | website=[[European Medicines Agency]] (EMA) | date=1 desembre 2020 | url=https://www.ema.europa.eu/en/news/ema-starts-rolling-review-janssens-covid-19-vaccine-ad26cov2s | access-date=1 desembre 2020}}</ref>
}}
▲* South Africa<ref>[https://www.msn.com/en-za/news/other/johnson-and-johnson-the-first-to-apply-for-covid-vaccine-registration-as-south-africa-starts-review-process/ar-BB1bZnjI "Johnson & Johnson the first to apply for Covid-19 vaccine registration as South Africa starts review process"] msn.com. 17 December 2020.</ref>}}
|- valign="top"
|'''NVX-CoV2373'''<wbr/><ref name="NCT04368988">{{ref-web|títol=Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant |url=https://clinicaltrials.gov/ct2/show/NCT04368988 |website=[[ClinicalTrials.gov]] |editor=[[United States National Library of Medicine]] |type=Registry |id=NCT04368988 |data= 30 abril 2020 |access-date= 14 juliol 2020 |archive-date= 14 juliol 2020 |archive-url=https://web.archive.org/web/20200714224741/https://clinicaltrials.gov/ct2/show/NCT04368988 |url-status=live }}</ref><br />[[Novavax]]
Linha 255 ⟶ 254:
}}
|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=131|description=Resposta amb adjuvant després de [[dosi de reforç]] d'[[Immunoglobulina G|IgG]] i [[anticòs neutralitzant]]<ref name="pmid32877576">{{ref-publicació| vauthors = Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H, Smith G, Patel N, Frieman MB, Haupt RE, Logue J, McGrath M, Weston S, Piedra PA, Desai C, Callahan K, Lewis M, Price-Abbott P, Formica N, Shinde V, Fries L, Lickliter JD, Griffin P, Wilkinson B, Glenn GM | display-authors=6 |títol= Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine |publicació= The New England Journal of Medicine |data= setembre 2020 |volum=383 |exemplar=24 |pàgines=2320–2332 | pmid = 32877576 | pmc = 7494251 | doi = 10.1056/NEJMoa2026920 }}</ref>}}
|{{Collapsible list|title=Emergència (1)|expand=yes
}}
|- valign="top"
|'''[[ZF2001]]''' '''(RBD-Dimer)<wbr />'''<ref name="london" /><br />Anhui Zhifei Longcom Biopharmaceutical Co. Ltd.
| |||